Alterity Therapeutics (ASX:ATH) has announced that a study recently published in the journal Neurotherapeutics demonstrated that its lead clinical asset, ATH434, was neuroprotective in a genetic model of Parkinson’s disease. …
Alterity’s ATH434 prevents loss of brain cells in Parkinson’s Disease animal model
January 31, 2023 Australian Biotech
Latest Video
New Stories
-
Who remembers the 'Vancouver' poster? We have a rerun
September 22, 2026 - - Latest News -
If there is a productivity gain in the process, then it should be passed on
September 22, 2026 - - Latest News -
Given the official use of AI, a cease and desist would not be unreasonable
September 22, 2026 - - Latest News -
Treasury has moved on from the PBS, but the policies built on its error have not
September 21, 2026 - - Latest News -
Nyrada banks $12 million as directors contribute in nearly half
September 21, 2026 - - Australian Biotech -
Telix announces takeover of ITM to create a global radiopharmaceutical powerhouse
September 21, 2026 - - Australian Biotech -
Only 2 per cent of Australians can name the signs of a heart condition behind one in four strokes
September 21, 2026 - - Latest News